Related Experiment Videos
Clinical experience with the Lillehei-Kaster valve prosthesis
Insights
The Lillehei-Kaster valve demonstrated moderate hospital mortality but offered significant long-term survival and clinical improvement for aortic and mitral valve replacement patients.
Area of Science:
- Cardiovascular Surgery
- Biomaterials Science
- Clinical Outcomes Research
Background:
- The Lillehei-Kaster valve is a mechanical prosthetic heart valve.
- Evaluating long-term outcomes of prosthetic valves is crucial for patient management.
Purpose of the Study:
- To assess the clinical outcomes, including mortality and thromboembolism, of the Lillehei-Kaster valve in patients undergoing aortic and mitral valve replacement.
Main Methods:
- Retrospective analysis of 215 patients who received the Lillehei-Kaster valve over a 7-year period.
- Separate evaluation of outcomes for aortic valve replacement (81 patients) and mitral valve replacement (108 patients).
- Data collection included hospital mortality, long-term mortality, thromboembolic events, and actuarial survival.
Main Results:
- Aortic valve replacement: 21% hospital mortality, 5% long-term mortality, 2.6/100 patient-years thromboembolism, 96% 5-year survival.
- Mitral valve replacement: 20% hospital mortality, 13% long-term mortality, 5.0/100 patient-years thromboembolism, 81% 5-year survival.
- Majority of patients experienced clinical improvement; 15 had double-valve replacement, 11 had concurrent coronary revascularization.
Conclusions:
- The Lillehei-Kaster valve provided acceptable long-term survival and clinical benefit for both aortic and mitral valve replacement, despite significant early mortality.
- Thromboembolism rates were observed in both patient groups.
- Further research may focus on optimizing anticoagulation strategies to mitigate thromboembolic risks.
Abstract:
The Lillehei-Kaster valve was used in 215 patients over a 7-year period. The aortic valve was replaced in 81 of them. Hospital mortality was 21% (17 patients). Ten patients were lost to follow-up and long-term mortality was 5% (3 patients). The incidence of thromboembolism was 2.6 per 100 patient-years, and actuarial survival was 96% at 5 and 87% at 7 years. Mitral valve replacement was performed in 108 patients. Hospital mortality was 20% (22 patients), 24 patients were lost to follow-up, and long-term mortality was 13% (11 patients). The combined incidence of thromboembolism was 5.0 per 100 patient-years, and actuarial survival was 81% at 5 years and 75% at 7 years. In both groups, the majority of patients improved clinically. Fifteen patients had double-valve replacement, and 11 had coronary revascularization in addition to valve replacement.